Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched this week, to help soften the blow when the original loses patent protection later this decade.

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...

An interim analysis of the TULIP-SC trial found that weekly subcutaneous delivery of Saphnelo significantly reduced disease activity in patients with moderate to severe SLE, offering a more convenient ...

Halozyme will purchase fellow subcutaneous drug delivery specialist Elektrofi for $750m upfront, along with with three ...

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing ...